Stock listing
Frankfurt:W33 BioVersys AG Aktie
German listing (Frankfurt) of BioVersys AG · home listing SIX Swiss:BIOV
Follow BioVersys AG into a list and get an email when it puts out news.
Share price · FWB:W33
€24.40 EUR -0.20 (-0.8%)
Close on Nov 20, 2026
- Day range
- €24.40 – €25.00 EURNov 20, 2026
- Market cap
- €142.9M EURAt the close on Nov 20, 2026 · price × 5.85M shares outstanding
- Traded on an average day
- €756 EURMedian day 0 shares · 47 days with no trades · last 3 months, Aug 20, 2026 – Nov 13, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| SIX Swiss:BIOV · Home | 22.10 CHF | -1.80 (-7.5%) | 9,078 | 23.50 | 23.90 | 22.10 | 23.90 | Close on Nov 20, 2026 |
| Frankfurt:W33 | €24.40 EUR | -0.20 (-0.8%) | — | €24.60 | €25.00 | €24.40 | €24.60 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 13, 2026 · FWB:W33 · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €24.50 | +0.739 | +3.1% | €23.99 | €24.63 | €23.90 | 0 | |
| €23.76 | -0.682 | -2.8% | €24.15 | €24.22 | €23.73 | 0 | |
| €24.44 | +0.269 | +1.1% | €24.60 | €24.68 | €24.40 | 9 | |
| €24.17 | +0.287 | +1.2% | €24.17 | €24.23 | €23.98 | 9 | |
| €23.89 | -0.14 | -0.6% | €24.11 | €24.23 | €23.69 | 9 | |
| €24.03 | +0.09 | +0.4% | €24.03 | €24.03 | €24.03 | 20 | |
| €23.94 | -0.219 | -0.9% | €24.11 | €24.23 | €23.84 | 0 | |
| €24.15 | -0.023 | -0.1% | €24.15 | €24.47 | €24.06 | 140 | |
| €24.18 | -0.453 | -1.8% | €24.64 | €25.18 | €24.16 | 0 | |
| €24.63 | -0.659 | -2.6% | €25.43 | €25.51 | €24.29 | 0 | |
| €25.29 | +0.117 | +0.5% | €25.20 | €25.39 | €25.15 | 0 | |
| €25.17 | +0.044 | +0.2% | €24.94 | €25.35 | €24.75 | 0 | |
| €25.13 | -0.075 | -0.3% | €25.13 | €25.93 | €24.78 | 0 | |
| €25.20 | -0.602 | -2.3% | €25.25 | €25.32 | €25.18 | 0 | |
| €25.81 | +0.152 | +0.6% | €25.20 | €26.01 | €25.10 | 0 | |
| €25.65 | -0.133 | -0.5% | €25.45 | €25.86 | €25.25 | 0 | |
| €25.79 | -0.458 | -1.7% | €25.80 | €25.86 | €25.77 | 0 | |
| €26.24 | +0.164 | +0.6% | €26.20 | €26.32 | €26.04 | 0 | |
| €26.08 | -0.143 | -0.5% | €26.08 | €26.08 | €26.08 | 0 | |
| €26.22 | -0.196 | -0.7% | €26.22 | €26.45 | €26.22 | 10 | |
| €26.42 | -0.411 | -1.5% | €26.42 | €26.42 | €26.42 | 0 | |
| €26.83 | +0.268 | +1.0% | €26.64 | €26.87 | €26.61 | 0 | |
| €26.56 | +0.314 | +1.2% | €26.20 | €26.57 | €25.98 | 0 | |
| €26.25 | -0.384 | -1.4% | €26.37 | €26.40 | €26.09 | 0 | |
| €26.63 | -0.211 | -0.8% | €26.63 | €26.63 | €26.63 | 0 | |
| €26.84 | +0.247 | +0.9% | €26.84 | €26.84 | €26.84 | 100 | |
| €26.60 | -0.416 | -1.5% | €26.60 | €26.60 | €26.60 | 100 | |
| €27.01 | -0.084 | -0.3% | €26.94 | €27.21 | €26.83 | 0 | |
| €27.10 | -0.311 | -1.1% | €26.93 | €27.13 | €26.76 | 0 | |
| €27.41 | +0.262 | +1.0% | €27.23 | €27.47 | €27.15 | 0 | |
| €27.15 | +0.654 | +2.5% | €27.28 | €29.84 | €26.98 | 17 | |
| €26.49 | -0.221 | -0.8% | €26.49 | €26.49 | €26.49 | 0 | |
| €26.71 | -1.137 | -4.1% | €26.47 | €26.73 | €26.40 | 0 | |
| €27.85 | +1.486 | +5.6% | €26.38 | €28.08 | €26.05 | 100 | |
| €26.36 | -0.825 | -3.0% | €25.90 | €26.48 | €25.90 | 0 | |
| €27.19 | +1.07 | +4.1% | €27.26 | €27.33 | €27.19 | 0 | |
| €26.12 | -1.549 | -5.6% | €26.23 | €26.25 | €25.92 | 0 | |
| €27.67 | -0.042 | -0.2% | €27.87 | €27.94 | €27.34 | 0 | |
| €27.71 | -0.553 | -2.0% | €27.71 | €27.73 | €27.60 | 0 | |
| €28.26 | +0.375 | +1.3% | €28.46 | €28.62 | €28.16 | 0 | |
| €27.89 | -0.266 | -0.9% | €27.89 | €27.89 | €27.88 | 0 | |
| €28.15 | +0.60 | +2.2% | €27.36 | €28.23 | €27.35 | 170 | |
| €27.55 | -1.429 | -4.9% | €27.62 | €27.62 | €27.44 | 0 | |
| €28.98 | +1.541 | +5.6% | €28.98 | €28.98 | €28.98 | 0 | |
| €27.44 | -0.123 | -0.4% | €27.74 | €27.74 | €27.43 | 0 | |
| €27.56 | -0.303 | -1.1% | €27.38 | €27.94 | €27.33 | 0 | |
| €27.87 | -0.465 | -1.6% | €28.07 | €28.10 | €27.79 | 0 | |
| €28.33 | -0.878 | -3.0% | €28.40 | €28.40 | €28.25 | 0 | |
| €29.21 | -0.293 | -1.0% | €29.21 | €29.39 | €28.92 | 0 | |
| €29.50 | +1.086 | +3.8% | €29.19 | €29.80 | €29.02 | 0 | |
| €28.42 | -0.462 | -1.6% | €28.42 | €28.48 | €28.15 | 0 | |
| €28.88 | -0.152 | -0.5% | €28.90 | €28.98 | €28.41 | 846 | |
| €29.03 | +3.374 | +13.2% | €27.92 | €29.41 | €27.77 | 50 | |
| €25.66 | +0.089 | +0.3% | €26.38 | €26.50 | €25.50 | 5 | |
| €25.57 | -0.99 | -3.7% | €26.35 | €26.43 | €25.42 | 0 | |
| €26.56 | +1.095 | +4.3% | €25.61 | €26.63 | €25.58 | 0 | |
| €25.46 | -0.516 | -2.0% | €26.29 | €26.39 | €25.15 | 0 | |
| €25.98 | -0.242 | -0.9% | €25.98 | €25.98 | €25.98 | 0 | |
| €26.22 | +0.295 | +1.1% | €25.79 | €26.23 | €25.77 | 0 | |
| €25.93 | -0.128 | -0.5% | €25.93 | €25.93 | €25.93 | 0 | |
| €26.05 | -0.81 | -3.0% | €26.05 | €26.05 | €26.05 | 0 | |
| €26.86 | -0.115 | -0.4% | €26.48 | €27.96 | €26.29 | 100 |
- Ticker
- Frankfurt:W33
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Frankfurt
- Currency
- EUR
What changed lately
Latest news release · Sep 9, 2026
BioVersys reports half-year 2026 results: BV100 pivotal RIV-TARGET trial actively recruiting, alpibectir Phase 2b/c underway, operations funded into 2028
Latest deck · Sep 9, 2026
Q3 2026 Earnings Presentation
Earnings · 46 slides
Latest news
BioVersys reports half-year 2026 results: BV100 pivotal RIV-TARGET trial actively recruiting, alpibectir Phase 2b/c underway, operations funded into 2028
Sep 9, 2026
Closed €28.33 (-3.0%) on Sep 9, 2026
BioVersys to Present at H.C. Wainwright 28th Annual Global Investment Conference
Sep 3, 2026
Closed €28.42 (-1.6%) on Sep 4, 2026
BioVersys granted Fast-Track Designation from US FDA for BV100
Sep 2, 2026
Closed €29.03 (+13.2%) on Sep 2, 2026
BioVersys to report its half-year 2026 financial results, provide a business update and host a conference call
Aug 26, 2026
Closed €25.98 (-0.9%) on Aug 26, 2026
BioVersys announces approval of all Board Proposals at Annual General Meeting of Shareholders
Apr 30, 2026
Closed €30.19 (-0.7%) on May 4, 2026
BioVersys completes BV100 Phase 1 clinical trial in China
Apr 22, 2026
Closed €30.54 (-1.1%) on Apr 22, 2026
BioVersys Announces First Patient First Visit in HABP/VABP Pivotal Phase 3 RIV-TARGET Trial of BV100
Apr 16, 2026
Closed €30.34 (+0.2%) on Apr 16, 2026
BioVersys to Present Data on Clinical and Preclinical Pipeline Programs at ESCMID Global 2026
Apr 15, 2026
Closed €30.28 (+4.0%) on Apr 15, 2026
Data Published in Nature Communications Highlights Unique Mechanism of Action of Alpibectir in Combination with Ethionamide (AlpE)
Apr 13, 2026
Closed €28.33 (+0.4%) on Apr 13, 2026
BioVersys Issues Invitation to its 2026 Annual General Meeting of Shareholders
Apr 7, 2026
Closed €29.07 (-4.4%) on Apr 7, 2026
BioVersys AG on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 19 in the last 12 months · 24 in all · newest Sep 9, 2026 · oldest 2025
- Decks
- 3 decks · latest Sep 9, 2026
Where BioVersys AG is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| SIX Swiss:BIOV · Home listing | SIX Swiss | Switzerland | CHF |
| Frankfurt:W33 · This page | Frankfurt | Germany | EUR |
| Turquoise:BIOVZ | Turquoise | United Kingdom | CHF |
Valuation
EV/sales 102× against a median of 45.5×: 7th lowest of 9 Biotechnology companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- 81.82M CHF
- P/E
- Loss
- EV/sales
- 102×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 2.9×
- Gross margin
- −386.6%
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- 0.5×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| BioVersys AG · SIX:BIOV | US$154.1M | US$97.45M | n/a | 102× | n/a | 2.9× | n/a | 0.5× | n/a |
| TaiGen Biopharmaceuticals Holdings Limited · TPEX:4157 | US$161.1M | US$133.4M | 34.2× | 17.1× | 46.8× | 5.2× | 60.5% | 0.0× | n/a |
| ImmuneOncia Therapeutics Inc. · KRX:424870 | US$160.0M | US$90.35M | n/a | n/a | n/a | 2.1× | n/a | 0.0× | n/a |
| Baijin Life Science Holdings Limited · HKEX:1466 | US$160.0M | US$158.1M | n/a | 13.9× | n/a | 6.8× | −42.4% | 0.1× | n/a |
| Jiangsu Recbio Technology Co., Ltd. Class H · HKEX:2179 | US$157.3M | US$230.0M | n/a | 124× | n/a | 2.1× | n/a | 1.4× | n/a |
| InflaRx N.V. · NASDAQ:IFRX | US$153.3M | US$135.7M | n/a | 4,215× | n/a | 19.5× | n/a | 0.0× | 1.61 |
| Polaris Group · TWSE:6550 | US$153.0M | US$154.8M | n/a | 75.1× | n/a | 1.1× | n/a | 0.5× | n/a |
| ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H · HKEX:1541 | US$152.0M | US$64.59M | n/a | 2.9× | n/a | 1.6× | −141.7% | 0.6× | n/a |
| Saniona AB · OMXSTO:SANION | US$151.6M | US$104.0M | 8.4× | 2.5× | 5.2× | 2.8× | 43.2% | 0.0× | n/a |
| Palisade Bio, Inc. · NASDAQ:PALI | US$150.6M | US$36.96M | n/a | 73.9× | n/a | 1.3× | n/a | 0.0× | 1.41 |
| Eledon Pharmaceuticals, Inc. · NASDAQ:ELDN | US$150.3M | US$80.67M | n/a | n/a | n/a | 4.9× | n/a | 0.0× | 1.95 |
| Median of the others | US$153.1M | US$118.7M | 21.3× | 45.5× | 26.0× | 2.5× | 0.4% | 0.0× | 1.61 |
Forecasts
Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.
- Price target
- 65.80 CHF · Analysts' mean
- EPS, year to Dec 2026
- -5.81 · 6 analysts
- Revenue, year to Dec 2026
- 3.22M · 5 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Marc Gitzinger | Chief Executive Officer & Founder |
| Hernan Levett | Chief Financial Officer |
| Anca Cighi | Head of Investor Relations and Communications |
| Alexander Lederer | Head of Intellectual Property |
| Daniel Ritz | Chief Scientific Officer |
| Fiona Gao | Head of Legal |
| Glenn Dale | Chief Development Officer |
| Jonathan James Butcher | Head of Business Development & Alliance Management |
Board
| Director | Role |
|---|---|
| Seng Chin Mah | Chairman |
| David Hunstad | Board Member |
| Marc Gitzinger | Chief Executive Officer & Founder |
| Marina von Schönau | Board Member |
| Simona Skerjanec | Board Member |
| Ulrik Schulze | Board Member |
Events
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Mar 31, 2026 | Apr 1, 2026 | +3.5% |
| Quarter to Sep 30, 2025 | Dec 3, 2025 | +7.7% |
| Q2 2025 | Sep 10, 2025 | −3.8% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q3 2026 Earnings Presentation | Earnings | 46 slides | Sep 9, 2026 |
| H1 2026 Earnings Presentation | Earnings | 21 slides | Sep 9, 2026 |
| FY2025 Earnings Presentation | Earnings | 27 slides | Mar 18, 2026 |
Financials
Annual, in CHF
Income statement
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | 800.0K | 0 |
| Cost of revenue | 3.89M | 3.95M |
| Gross profit | -3.09M | -3.95M |
| Research and development | 16.5M | 12.9M |
| Operating income | -20.0M | -18.7M |
| Depreciation and amortization | 297.0K | 282.0K |
| EBITDA | -19.7M | -18.4M |
| Interest expense | 1.08M | 1.04M |
| Income before tax | -21.8M | -18.7M |
| Net income | -21.8M | -18.7M |
| Earnings per share, basic | -3.73 | -3.16 |
Balance sheet
| Line | FY2025 | FY2024 |
|---|---|---|
| Cash and equivalents | 82.5M | 26.6M |
| Short-term investments | 6.00M | |
| Current assets | 89.9M | 34.4M |
| Total assets | 90.6M | 35.0M |
| Accounts payable | 2.47M | 706.0K |
| Current liabilities | 8.90M | 9.67M |
| Long-term debt | 21.3M | 13.6M |
| Total liabilities | 30.8M | 24.3M |
| Shareholders' equity | 59.8M | 10.7M |
| Shares outstanding | 5.85M | 5.91M |
Cash flow
| Line | FY2025 | FY2024 |
|---|---|---|
| Cash from operations | -21.9M | -15.6M |
| Capital spending | -216.0K | -38.0K |
| Free cash flow | -22.2M | -15.6M |
| Change in cash | 56.4M | 1.58M |
Cap table
Built by 6ix from BioVersys AG’s releases
- Common shares
- 5,854,584
- Fully diluted
- 5,854,584
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 5,854,584 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 5,854,584 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Alexander Lederer | Head of Intellectual Property · Since at least Nov 5, 2026 |
| Anca Cighi | Head of Investor Relations and Communications · Since at least Apr 2, 2026 |
| Daniel Ritz | Chief Scientific Officer · Since at least Mar 31, 2026 |
| David Hunstad | Board Member · Since at least Apr 30, 2026 |
| Fiona Gao | Head of Legal · Since at least Nov 5, 2026 |
| Glenn Dale | Chief Development Officer · Since at least Apr 22, 2026 |
| Hernan Levett | Chief Financial Officer · Since at least Sep 9, 2026 |
| Jonathan James Butcher | Head of Business Development & Alliance Management · Since at least Nov 4, 2026 |
| Marc Gitzinger | Chief Executive Officer & Founder · Since at least Sep 9, 2026 |
| Marina von Schönau | Board Member · Since at least Apr 30, 2026 |
All 13 people
| Person | Seat |
|---|---|
| Seng Chin Mah | Chairman · Since at least Apr 30, 2026 |
| Simona Skerjanec | Board Member · Since at least Apr 30, 2026 |
| Ulrik Schulze | Board Member · Since at least Apr 30, 2026 |
Log in to ask 6ix AI your own questions about BioVersys AG.